PETReA Plus: A observational study of treatment and outcomes for people with newly diagnosed follicular lymphoma
This trial is collecting long term information people newly diagnosed with follicular lymphoma who are due to start treatment.
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: ISRCTN80351925
Trial aim and background
The aim of this trial is to collect the following information:
- duration of time until the follicular lymphoma (FL) worsens based on the FL stage, grade and first line treatment used
the length of time until the FL returns after treatment (relapses) or stops responding to treatment (refractory) and the overall survival based on the FL stage, grade and first line treatment use - what first line treatments are used for different patient characteristics and FL stage and grade
- what second line treatments are used and how effective they are
- how often maintenance antibody therapy is used and the reasons it is stopped
- how often PET scans are used for initial staging
- what the serious side effects are for the treatments used
- what people with FL QoL is like during treatment
The trial will enrol all people with newly diagnosed follicular lymphoma who are receiving their first treatment. Data will be collected during the patient’s clinic visits. Other than quality of life (QoL) questionnaires, no extra tests or assessments will be carried out.
Who can enter
Adults with grade 1, 2, 3A or 3B follicular lymphoma who have had a diagnostic biopsy within the last 6 months and have any planned treatment (including watch and wait) may be eligible for this trial.
Locations
Recruitment is taking place at the following UK locations:
- Southampton General Hospital, Southampton
- Arrowe Park Hospital, Wirral
- Clatterbridge Hospital, Wirral
- Derriford Hospital, Derriford
- Kent and Canterbury Hospital, Canterbury
- Northern General Hospital NHS Trust, Sheffield
- John Radcliffe Hospital, Oxford
- Croydon University Hospital, London
- Forth Valley, Stirling
- Poole Hospital, Poole
- Musgrove Park Hospital, Taunton
- Leicester Royal Infirmary, Leicester
- University College London Hospitals NHS Foundation Trust, London
- The Royal London Hospital, London
- Betsi Cadwaladr University Lhb, Bangor
- Colchester District General Hospital, Colchester
- The Christie NHS Foundation Trust, Manchester
- Victoria Hospital, Blackpool
- Gartnavel Royal Hospital, Glasgow
- Guy’s and St Thomas’ NHS Foundation Trust, London
- Belfast City Hospital, Belfast
- Queen Elizabeth Hospital, Birmingham
- Sandwell Health Campus, West Bromwich
- Milton Keynes Hospital, Milton Keynes
- Salford Royal Hospital, Salford
- Royal Cornwall Hospital, Truro
- Russells Hall Hospital, Dudley
- Queens Hospital, Burton-on-Trent
- Peterborough City Hospital, Peterborough
- Hinchingbrooke Hospital, Huntingdon
- The Royal Oldham Hospital, Oldham
- Pilgrim Hospital, Boston
- Lincoln County Hospital, Lincoln
- Good Hope Hospital, Sutton Coldfield
- Hywel Dda University Health Board, Carmarthen
- West Middlesex University Hospital, Isleworth
- Queen Alexandra Hospital, Portsmouth
- Nottingham City Hospital, Nottingham
- St Helier Hospital, Surrey
- Barnet & Chase Farm Hospitals, Enfield
- University Hospital of Wales, Cardiff
- Grantham and District Hospital, Grantham
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:
https://www.isrctn.com/ISRCTN80351925
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.